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E D I T O R I A L
Genomic momentum for hemostasis and thrombosis
As biomedical scientists and clinicians, we are fortunate to live at a 
time when the potential translational benefits of genetic knowledge 
have never been better. When Francis Crick wrote to his son Michael 
in 1953, informing him that, “Jim Watson and I have probably made a 
most important discovery…Our structure is very beautiful”, one sus‐
pects that not even he could have predicted the advances that would 
derive from this revelation over the next 65 years.
Since the initial publication of the Human Genome Project re‐
sults in 2001 and the subsequent utility of next generation sequenc‐
ing approaches in the past decade, the speed of genomic knowledge 
advancement has been remarkable. The field of hemostasis and 
thrombosis has remained at the forefront of these advances since 
the early 1980s when the genes implicated in the most common in‐
herited bleeding disorders, F8, F9 and VWF, were among the first 
human genes to be cloned and characterized. Soon after these dis‐
coveries, initial molecular genetic testing became available for the 
hemophilias and von Willebrand disease, and recombinant clotting 
factor concentrates were first used as replacement therapies in he‐
mophilia in 1989.
Against this background of enthusiastic engagement in genomic 
science of the thrombosis and hemostasis community, a new Scientific 
and Standardisation subcommittee of ISTH was proposed in 2011. 
This initiative was led by Willem Ouwehand, who subsequently be‐
came the first chairperson of the SSC on Genomics in Thrombosis 
and Hemostasis. In this issue of the journal, this Subcommittee re‐
ports their progress in curating a list of disease‐causing genes for 
bleeding, thrombosis, and platelet disorders (BTPD).
The SSC initiative to generate a list of curated genes causing 
BTPDs began in 2014 and the current list includes 91 genes that 
are inherited as germline mutations (the PIGA gene that acquires 
somatic mutations in paroxysmal nocturnal hemoglobinuria is the 
single non‐germline association). Of this list of 91 disease‐causing 
genes, 21 result in coagulation factor deficiencies and bleeding, 9 
in thrombotic disease and 61 in disorders of platelet number and/or 
function. This list only includes Tier 1 or diagnostic grade genes that 
have been identified through the application of the following cri‐
teria: evidence of supportive genotype‐phenotype co‐segregation 
in at least three genetically independent families, robust support 
from functional studies and/or a mouse model that recapitulates 
the human phenotype where less than three affected families are 
known.
Tier 2 and 3 genes represent loci for which peer‐reviewed liter‐
ature support is limited often to single kindreds, and for which func‐
tional studies and/or mouse models have yet to provide conclusive 
evidence to be linked to a human disease resulting in bleeding or 
thrombosis. While the current list of 91 curated Tier 1 genes provides 
the thrombosis and hemostasis community with a substantial founda‐
tion to initiate molecular diagnostic testing in patients and their fami‐
lies, a sustained effort will be required to review the status of current 
Tier 2 and 3 genes, and other newly identified loci with possible hemo‐
static associations. This effort has recently been aided by the estab‐
lishment, in 2017, of a Clinical Domain Working Group for Thrombosis 
and Hemostasis within the Clinical Genome Resource, ClinGen. This 
Working Group has a substantial ISTH connection.
In 2019, the molecular testing for patients with inherited BTPDs 
is increasingly likely to involve a next generation sequencing gene 
panel strategy, with the simultaneous evaluation of all 91 candidate 
Tier 1 genes. The information derived from these studies can be ap‐
plied to personal and family counseling, optimization of therapy and 
disease prognostication.
Overall, over the past decade, enormous progress has been 
made in advancing our genomic knowledge of BTPD causing genes. 
However, as is often the case with genetic advances, caution must 
be maintained where the possibility of incidental findings may have 
long‐term consequences such as the association of premalignant ge‐
netic variants in some genes causing inherited thrombocytopenia. 
Nevertheless, in aggregate, the advances in genomic science in our 
field have undoubtedly been beneficial, both in terms of increasing 
scientific knowledge and in its application to clinical care. The ISTH 
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